The genomic assay will now be available for full reimbursement for patients with HR+/HER2 negative early-stage breast cancer ...
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
Low blood pressure, also known as hypotension, occurs when blood flows through your blood vessels at pressures that are lower than normal. Low blood pressure is primarily a concern if it produces ...
If you’ve been diagnosed with or are at risk for high cholesterol (meaning you have too much of this waxy substance in your blood), your doctor may recommend a low-cholesterol diet. Learn what a ...
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...